Cormorant Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Cormorant Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41M	Sell	550,000 -300,000	-35%	-$21M	2.1%	16
2026 Q1	$63.1M	Sell	850,000 -350,000	-29%	-$25.4M	3.17%	12
2025 Q4	$91.8M	Sell	1,200,000 -200,000	-14%	-$13.1M	4.24%	9
2025 Q3	$72.7M	Sell	1,400,000 -200,000	-13%	-$9.75M	5.02%	5
2025 Q2	$69.1M	Sell	1,600,000 -400,000	-20%	-$14.5M	5.15%	3
2025 Q1	$69.1M	Buy	2,000,000 +400,000	+25%	+$13.5M	5.2%	3
2024 Q4	$43.9M	Sell	1,600,000 -258,351	-14%	-$6.68M	2.41%	11
2024 Q3	$47.3M	Hold	1,858,351	–	–	2.51%	13
2024 Q2	$47.1M	Sell	1,858,351 -1,344,678	-42%	-$36.8M	2.72%	11
2024 Q1	$99M	Sell	3,203,029 -141,150	-4%	-$4.8M	4.34%	5
2023 Q4	$135M	Sell	3,344,179 -1,318,351	-28%	-$39.6M	6.45%	4
2023 Q3	$123M	Buy	4,662,530 +493,351	+12%	+$14M	7.17%	2
2023 Q2	$71.7M	Sell	4,169,179 -388,235	-9%	-$5.84M	4.02%	5
2023 Q1	$75.6M	Buy	4,557,414 +3,188,235	+233%	+$37.2M	4.98%	6
2022 Q4	$10.4M	Sell	1,369,179 -100,000	-7%	-$957K	0.7%	37
2022 Q3	$14.6M	Hold	1,469,179	–	–	1.02%	34
2022 Q2	$13.3M	Sell	1,469,179 -99,730	-6%	-$834K	1.01%	33
2022 Q1	$15.9M	Sell	1,568,909 -100,000	-6%	-$1.03M	1.22%	23
2021 Q4	$27.8M	Sell	1,668,909 -100,000	-6%	-$4.23M	1.66%	21
2021 Q3	$82.9M	Sell	1,768,909 -112,071	-6%	-$6.01M	3.37%	7
2021 Q2	$115M	Sell	1,880,980 -287,929	-13%	-$16.4M	3.9%	5
2021 Q1	$134M	Sell	2,168,909 -96,853	-4%	-$6.34M	2.98%	7
2020 Q4	$161M	Hold	2,265,762	–	–	3.83%	6
2020 Q3	$85M	Sell	2,265,762 -325,000	-13%	-$10.2M	3.27%	5
2020 Q2	$84.5M	Sell	2,590,762 -359,238	-12%	-$10.9M	3.22%	6
2020 Q1	$85.5M	Buy	2,950,000 +437,135	+17%	+$13.6M	3.98%	4
2019 Q4	$88.1M	Sell	2,512,865 -104,701	-4%	-$2.9M	3.51%	7
2019 Q3	$56.2M	Sell	2,617,566 -163,319	-6%	-$4.52M	3.42%	6
2019 Q2	$75M	Buy	+2,780,885	New	+$75.8M	4.31%	6

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cormorant Asset Management's BBIO Position: Q2 2026 in Review

Cormorant Asset Management reduced its BridgeBio Pharma (BBIO) stake by 35% in Q2 2026, selling an estimated $21M and leaving 550,000 shares worth $41M. The position accounts for 2.1% of the portfolio, ranked #16.

Cormorant Asset Management first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $161M in Q4 2020. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Cormorant Asset Management held 550,000 shares of BridgeBio Pharma worth $41M as of Q2 2026.
Cormorant Asset Management sold 300,000 BridgeBio Pharma shares in Q2 2026, an estimated $21M.
BridgeBio Pharma made up 2.1% of Cormorant Asset Management's portfolio in Q2 2026, its #16 holding.
Cormorant Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
Cormorant Asset Management's BridgeBio Pharma position peaked at $161M in Q4 2020.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.